Mammalian cell-based production of glycans, glycopeptides and glycomodules

基于哺乳动物细胞的聚糖、糖肽和糖模块的生产

阅读:8
作者:Thapakorn Jaroentomeechai, Richard Karlsson, Felix Goerdeler, Fallen Kai Yik Teoh, Magnus Nørregaard Grønset, Dylan de Wit, Yen-Hsi Chen, Sanae Furukawa, Venetia Psomiadou, Ramon Hurtado-Guerrero, Elena Ethel Vidal-Calvo, Ali Salanti, Thomas J Boltje, Leendert J van den Bos, Christian Wunder, Ludger

Abstract

Access to defined glycans and glycoconjugates is pivotal for discovery, dissection, and harnessing of a range of biological functions orchestrated by cellular glycosylation processes and the glycome. We previously employed genetic glycoengineering by nuclease-based gene editing to develop sustainable production of designer glycoprotein therapeutics and cell-based glycan arrays that display glycans in their natural context at the cell surface. However, access to human glycans in formats and quantities that allow structural studies of molecular interactions and use of glycans in biomedical applications currently rely on chemical and chemoenzymatic syntheses associated with considerable labor, waste, and costs. Here, we develop a sustainable and scalable method for production of glycans in glycoengineered mammalian cells by employing secreted Glycocarriers with repeat glycosylation acceptor sequence motifs for different glycans. The Glycocarrier technology provides a flexible production platform for glycans in different formats, including oligosaccharides, glycopeptides, and multimeric glycomodules, and offers wide opportunities for use in bioassays and biomedical applications.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。